Novel tricyclic-α-alkyloxyphenylpropionic acids: Dual PPARα/γ agonists with hypolipidemic and antidiabetic activity

Journal of Medicinal Chemistry

Volumn 45, Issue 4, 2002, Pages 789-804

  Sauerberg, Per ^a   Pettersson, Ingrid ^a   Jeppesen, Lone ^a   Bury, Paul S ^a   Mogensen, John P ^a   Wassermann, Karsten ^a   Brand, Christian L ^a   Sturis, Jeppe ^a   Wöldike, Helle F ^a   Fleckner, Jan ^a   Andersen, Anne Sofie T ^a   Mortensen, Steen B ^a   Svensson, L Anders ^a   Rasmussen, Hanne B ^a   Lehmann, Søren V ^a   Polivka, Zdenek ^b   Sindelar, Karel ^b   Panajotova, Vladimira ^b   Ynddal, Lars ^a   Wulff, Erik M ^a  

^a NOVO NORDISK A S   (Denmark)

^b RE and D VUFB   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

3 [4 (2 CARBAZOL 9 YLETHOXY)PHENYL] 2 ETHOXYPROPIONIC ACID; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; BEZAFIBRATE; CARBACYCLIN; CARBAZOLE DERIVATIVE; CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHENYLPROPIONIC ACID DERIVATIVE; PIOGLITAZONE; PIRINIXIC ACID; RAGAGLITAZAR; ROSIGLITAZONE; TRIACYLGLYCEROL; TROGLITAZONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; COMPUTER MODEL; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG ACTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; INSULIN SENSITIVITY; MALE; MOUSE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; STRUCTURE ACTIVITY RELATION; TRANSACTIVATION; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ANTILIPEMIC AGENTS; BLOOD GLUCOSE; CARBAZOLES; CHOLESTEROL; CHOLESTEROL, DIETARY; CRYSTALLOGRAPHY, X-RAY; DRUG EVALUATION, PRECLINICAL; GLUCOSE TOLERANCE TEST; HYPOGLYCEMIC AGENTS; MALE; MICE; MODELS, MOLECULAR; NUCLEAR PROTEINS; PHENYLPROPIONATES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS; TRIGLYCERIDES;

EID: 0037075146     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm010964g     Document Type: Article

References (62)

1. Diabetes complications: Why is glucose potentially roxic?
2. Mechanism of action of fibrates on lipid and lipoprotein metabolism
3. WHO cooperative trial on the primary prevention of ischemic heart disease with clofibrate to lower serum cholesterol: Final mortality follow-up
4. Effect of bezafibrate treatment over five years on coronary plaques causing 20% to 50% diameter narrowing (the bezafibrate coronary atherosclerosis intervention trial [BECAIT])
5. Treatment effects on serum lipoprotein lipids, apolipoproteins and lowdensity lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the bezafibrate coronary atherosclerosis intervention trial (BECAIT)
6. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
7. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: The diabetes atherosclerosis intervention study, a randomised study
8. Improvement of glucose tolerance in NIDDM by clofibrate. Randomized double-blind study
9. Lowering of plasma glucose concentrations with bezafibrate in patients with moderately controlled NIDDM
10. Improvement of glucose tolerance by bezafibrate in nonobese patients with hyperlipidemia and impaired glucose tolerance
11. Decreased susceptibility to copper-induced oxidation of rat-lipoproteins after fibrate treatment: Influence of fatty acid composition
12. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes
13. Relationship between HbA1c and weight in the treatment of patients with type 2 diabetes
14. The structure-activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones
15. A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARα agonist with potent lipid-lowering activity
16. N-(2-benzoylphenyl)-L-tyrosine PPARγ agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents
17. N-(2-benzoylphenyl)-L-tyrosine PPARγ agonists. 2. Structure-activity relationship and optimization of the phenyl alkyl ether moiety
18. N-(2-benzoylphenyl)-L-tyrosine PPARγ agonists. 3. Structure-activity relationship and optimization of the N-aryl substituent
19. A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-α (PPAR-α) and PPAR-γ: Effect of PPAR-α activation on abnormal lipid metabolism in liver of Zucker fatty rats
20. (3-Substituted benzyl)-thiazolidine-2,4-diones as structurally new antihyperglycemic agents
21. Design and synthesis of 2-methyl-2-{4-[2-(5-methyl-2-aryloxazol-4-yl)ethoxy] phenoxy}propionic acids: A new class of dual PPARα/γ agonists
22. (-)3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid [(-)DRF2725]: A dual PPAR agonist with potent antihyperglycemic and lipid modulating activity
23. Studies on antidiabetic agents. VI. Asymmetric transformation of (±)-5-[4- (1-methylcyclohexylmethoxy)benzyl]benzyl]-2,4-thiazolidinedione (ciglitazone) with optically active 1-phenylethylamines
24. Differential activity of rosiglitazone enantiomers at PPARγ
25. Nonthiazolidinedione antihyperglycemic agents. 1: α-heteroatom substituted β-phenylpropanoic acids
26. Nonthiazolidinedione antihyperglycemic agents 2: α-carbon substituted β-phenylpropanoic acids
27. The PPARs: From orphan receptors to drug discovery
28. Hypoglycemic activity of a series of α-alkylthio and α-alkoxy carboxylic acids related to ciglitazone
29. Nonthiazolidinedione antihyperglycaemic agents. Part 4: Synthesis of (±)-, R-(+)-and (S)-(-)-enantiomers of 2-oxy-3-arylpropionic acids
30. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma
31. Nonthiazolidinedione antihyperglycaemic agents. Part 3: The effects of stereochemistry on the potency of α-methoxy-β-phenylpropionic acids
32. Novel euglycemic and hyperlipidemic agents. 1
33. A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation
34. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors
35. Merck molecular-force field. 1. Basis form scope parametrization and performance of mmff94
36. Merck molecular-force field. 2. mmff94 van der Waals and electrostatic parameters for intermolecular interactions
37. Merck molecular-force field. 3. Molecular geometries and vibrational frequencies for mmff94
38. Merck molecular-force field. 4. Conformational energies and geometries for mmff94
39. MacroMedel-an integrated software system for modeling organic and bioorganic molecules using molecular mechanics
40. Rosiglitazone once or twice daily improves glycemic control in patients with type 2 diabetes (T2D)
41. Lack of predictability of classical animal models for hypolididemic activity: A good time for the mice?
42. 3-(4-Methylpiperazino)dibenzo[b,f]-1,2,4-trazolo-[4,3-d]-1,4-thiazepine and its 6-chloro and 12-chloro derivatives; synthesis and pharmacology
43. Spasmolytics derived from xanthen
44. 3-column
45. Studies on the alkylation and chlorination of fluorenes: Preparation of 9-(2-hydroxyethyl)fluorene and 2,7-dichloro-9-(2-hydroxyethyl)fluorene
46. The homoallylic rearangement in the synthesis of amitriptyline and related systems
47. Synthesis of a cyclopropyl carbinol in the amitripyline series
48. GAL4 fusion vectors for expression in yeast and mammalian cells
49. The yeast UASG is a transcriptional enhancer in human HeLa cells in the presence of the GAL4 trans-activator
50. The crystallography beamline I711 at MAX II
51. Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants
52. Slow-cooling protocols for crystallographic refinement by simulated annealing
53. Analysis of c-alpha geometry in protein structures
54. Databases in protein crystallography
55. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules
56. New hydrogen-bond potentials for use in determining energetically favorable binding sites on molecules of known structure
57. Further development of hydrogen bond functions for use in determining energetically favorable binding sites on molecules of known structure. 2. Ligand probe groups with the ability to form more than two hydrogen bonds
58. Semianalytical treatment of solvation for molecular mechanics and dynamics
59. An unbounded systematic search of conformational space